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Identification of persons at high risk for kidney disease via will almost double to approximately 661,330 individuals
targeted screening: The NKF Kidney Early Evaluation Pro- by the year 2010 [2].
gram. Chronic kidney disease and the development of ESRDBackground. More than 340,000 individuals were receiving
due to type 2 diabetes mellitus and hypertension arerenal replacement therapy in the United States at the end of
particularly common in minority populations. African1999; this number is projected to double by the year 2010.
Almost half had a primary diagnosis of diabetes mellitus partic- Americans have a 3 to 7 times greater risk of kidney
ularly type 2, and more than one quarter a primary diagnosis disease than Caucasians, even for the same diagnosis
of hypertension. Studies have demonstrated effective maneu-
[3–5]. Although the incidence is increasing for bothvers to prevent or delay the rate of progression of kidney
groups there is a clear disparity, with ESRD secondarydisease, and decrease morbidity and mortality. The objective
of early diagnosis is early detection of asymptomatic disease to both hypertension and diabetes increasing at a much
at a time when intervention has a reasonable potential to have greater rate in African Americans [1]. Hispanic Ameri-
a positive impact on outcome. cans, Native Americans, Mexican Americans and AsianMethods. In 1997, the National Kidney Foundation launched
Americans are also at increased risk (Fig. 1) [1]. Of NativeKEEP (Kidney Early Evaluation Program), a free commu-
Americans and Hispanic Americans receiving renal re-nity-based screening that targets first order relatives of persons
with hypertension, diabetes or kidney disease, and those with placement therapy, almost 70% and 60%, respectively,
a personal history of diabetes or hypertension. have a primary diagnosis of diabetes [1]. In addition,
Results. Of the 889 individuals screened in the pilot study,
many of these minority individuals are socioeconomi-71.4% had at least one abnormality. The program includes an
cally disadvantaged and may lack health insurance andeducational component and referral to a physician for follow-
up of abnormal values. have limited access to health care [6, 7].
Conclusions. Targeted screenings are an effective means of One in nine Americans, more than 20 million people,
identifying persons at risk for kidney disease, and can identify has kidney disease; most don’t know it [8, 9]. Anotherindividuals at risk early enough in the course of their disease
20 million Americans are at increased risk of kidneyto allow for effective intervention.
disease [8]. Population surveys demonstrate that most
of these individuals with kidney disease or at risk for
kidney disease are unaware of their risk [9]. In addition,More than 340,000 individuals were receiving renal
patients with chronic kidney disease have a significantlyreplacement therapy in the United States on December
increased risk for cardiovascular events [8, 10]. The med-31, 1999 at a cost of $17.9 billion [1]. More than 45%
ical costs and cost of lost productivity for these individu-of incident ESRD patients had a primary diagnosis of
diabetes mellitus, and more than 26% had a primary als are enormous.
diagnosis of hypertension [1]. It is projected that the It has been predicted that in the next 10 years there
number of patients requiring renal replacement therapy will be a 50% increase in the number of adult Americans
with diabetes [11]; 25 to 40% of these individuals will
develop kidney disease. Type 2 diabetes in children andKey words: KEEP, chronic kidney disease, screening, diabetes, hyper-
tension, early intervention. adolescents has increased more than tenfold in the last
decade [12–14] and correlates with increasing obesity, 2003 by the International Society of Nephrology
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Fig. 1. Dialysis incident rates by primary diagnosis and race.
poor dietary habits, lack of physical activity and a family diastolic blood pressure90 mm Hg or current anti-hyper-
history of type 2 diabetes in first- or second-degree rela- tensive therapy with prescription medication [9, 50]. Of
tives [14–19]. As in adults, the prevalence and rate of these individuals with hypertension, almost half have
increase of type 2 diabetes in young children is greatest not been prescribed medication, about one quarter have
in minority populations [14–18, 20–22]. Total direct and been prescribed medication, but their blood pressure is
indirect costs of caring for these patients with chronic not controlled, and only a quarter are on medication and
kidney disease, exclusive of ESRD, exceeded $92 billion controlled [9]. Hyman and Pavlik noted most cases of
in 1992 [23]. uncontrolled hypertension occurred in individuals who
“have access to health care and relatively frequent con-
tact with physicians” [50]. A study of over 1400 hyperten-EFFECTIVE INTERVENTIONS TO PREVENT
sive patients with chronic kidney disease enrolled in theOR DELAY PROGRESSION OF
Modification of Diet in Renal Disease Study (MDRD)KIDNEY DISEASE
revealed that 91.5% were treated with anti-hypertensive
The objective of early diagnosis is the early detection medication [51]. Unfortunately, only 54% of these pa-
of asymptomatic disease when intervention has a reason-
tients had a blood pressure less than or equal to 140/90
able potential to have a positive impact on outcome.
mm Hg, a threshold which is well above the target bloodNumerous studies have demonstrated that effective ma-
pressure of 125/75 mm Hg for persons with chronicneuvers exist to prevent or delay the rate of progression
kidney disease with proteinuria.of kidney disease [11–24], and decrease morbidity and
A retrospective chart review of hospitalized Medicaremortality [25]. Excellent glycemic control in those with
beneficiaries with a primary or secondary diagnosis ofdiabetes [26–28], aggressive blood pressure control
diabetes or hypertension found low rates of screening[29–33], correction of dyslipidemias [34, 35], phospho-
for kidney disease in this population. When evidence ofrous control [36], reduction of proteinuria with angioten-
kidney disease was found, it was documented at dis-sin converting enzyme (ACE) inhibitors and/or angio-
charge in less than 10% of patients with diabetes and lesstensin receptor blockers [37–43], reduction of cardiac
than 13% of those with hypertension, although 24.9% ofrisk factors [44], appropriate diet [45–47] and lifestyle
those with diabetes had a serum creatinine 1.3 mg/dLmodification [48, 49] are some of the interventions that
and 31.3% had proteinuria1, and 21.9% of those withhave been shown to be effective.
hypertension had a serum creatinine 1.3 mg/dL and
8.3% proteinuria 1. Only a third of diabetic patients
TRANSLATION OF CLINICAL ADVANCES and 12.5% of hypertensive patients with 1 protein-
INTO CLINICAL PRACTICE uria were prescribed ACE inhibitors at discharge [52].
Unfortunately, the use of interventions to delay or
prevent progression of kidney disease does not translate
IMPACT OF LATE DIAGNOSIS, SUBOPTIMALinto clinical practice. Approximately one quarter of the
TREATMENT AND LATE REFERRALadult United States population, more than 43 million
Because of the failure to recognize early kidney dis-individuals, has a diagnosis of hypertension, defined as
a mean systolic blood pressure 140 mm Hg, a mean ease potentially beneficial interventions are not insti-
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Table 1. Ethnic distribution of KEEP participantstuted. This results in increased morbidity and mortality
Aleutian/Alaska Native/Eskimo/American Indian 0.4%[11, 53, 54], and greater cost to the patient and society.
Asian 3.8%Furthermore, those who develop ESRD have a longer
African American 53.2%
initial hospitalization, are not appropriately educated Pacific Islander 2.8%
Caucasian 29.1%about choice of modality and come to dialysis without
Other/Not stated 10.7%dialysis access [53, 55].
GENESIS OF KEEP
inine in a central laboratory. Random urine specimensA mass, untargeted screening rarely captures more
were collected and tested by the dipstick method forthan a few percent of the eligible population, is not
pyuria, hematuria and microalbuminuria. Creatininecost-effective and is an inefficient use of resources (R
clearance was calculated using the Cockcroft-Gault for-Glassock, personal communication; unpublished data
mula [59].from C.A.R.E.: Computerized Assessment Risk Educa-
A physician reviewed all screening results except se-tion, also known as the “Indiana Project”) [56, 57]. In
rum creatinine with participants on site, and they were1991, the National Kidney Foundation of Indiana, in
given a copy of their test results. Those with test resultscollaboration with the Diabetes Research and Training
outside the normal range were encouraged to follow-upCenter of Indiana University, developed a unique early
with a physician and given a letter to present to theirdetection, intervention and prevention initiative for per-
physician indicating the reason(s) for referral. Referralsons at increased risk for kidney disease. They screened
to local clinics or physicians was provided for individualsfirst order relatives of dialysis patients with diabetes
without a physician and/or health insurance. Educationaland/or hypertension and found that 56% of 348 Indiana
materials about kidney disease, hypertension and diabe-participants were at risk of diabetes, hypertension and/or
tes were provided to all participants. The NKF conductedkidney disease. Indiana’s data seemed to support the
one and three month follow-up by telephone, to ascertainidea that targeted screenings identify a greater number
whether follow up had occurred.of individuals at risk than a general public screening
(unpublished data; CARE, ibid). This project was ulti-
mately adapted by the National Kidney Foundation and
RESULTS
a national program was developed, the Kidney Early
Of the 889 individuals screened, 293 (33%) were maleEvaluation Program.
and 596 (67%) female. Participants ranged in age from
18 to over 85 years of age with the majority between 26
KEEP PILOT and 64 years. Twenty-five per cent had a family history
of kidney disease, 72.9% a family history of hypertensionThe KEEP Pilot was a free, community-based screen-
and 57.5% a family history of diabetes. Fifty-one pering that took place in 21 cities in 1997. The objective
cent gave a history of pre-existing disease: 28.9% hyper-was to identify persons at risk for kidney disease by
tension and 18.9% diabetes. Only 43 individuals gave ascreening persons with first order relatives with diabetes,
history of known kidney disease (4.8%). The types ofhypertension or kidney disease, or those with a personal
pre-existing disease and the percentages reporting pre-history of diabetes or hypertension.
existing disease did not differ by ethnicity. Ethnicity ofScreenings were advertised via local media, and infor-
the participants is shown in Table 1.mation provided to dialysis patients, with an emphasis on
Six hundred thirty-six individuals (71.4%) had abnor-minority communities. Screening sites included churches,
mal test values and were encouraged to follow-up withhospitals, health centers, schools, community centers and
a doctor. Three hundred ninety-four individuals (44.3%)dialysis units. Participants signed a consent form and
had two or more values outside the normal range andcompleted a Health Risk Assessment questionnaire. Eli-
514 (57.8%) learned of at least one new condition. Tablegibility criteria for screening were age 18 years or older,
2 shows the values outside the normal range for eachand a first-degree relative with diabetes, hypertension
screening test and the individuals who were found toor kidney disease or a personal history of diabetes or
have a single abnormal value and had no prior historyhypertension. Participants were weighed and blood pres-
of disease. Table 3 identifies the number of participantssure measured by the method presented in the Sixth
learning of one or more risk factors for diabetes, hyper-Report of the Joint National Committee on Prevention,
tension and/or kidney disease. There were 420 individu-Detection, Evaluation and Treatment of High Blood
als identified with markers for kidney disease, some ofPressure [58].
whom had more than one abnormality: 114 had an ele-Blood glucose levels were tested using capillary blood
and blood was obtained for measurement of serum creat- vated serum creatinine (1/4 of whom had a serum creati-
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Table 4. Screening diagnoses confirmed by participants’ physicianTable 2. Values outside of the normal range for each screening test
Single abnormal value—no Diagnosis Number of participants
prior history of disease
Abnormal value Diabetes mellitus 3
Hypertension 24Screening test N of subjects N of subjects Percent
Kidney disease 6
Serum glucose 113 14 6.0 Advanced kidney disease 2
Microalbuminuria 188 27 11.6 Referred to dialysis 1
Pyuria 148 33 14.2
Hematuria 179 48 20.6
↑ Serum creatinine 126 37 15.9
Diastolic hypertension 259 22 9.4
Systolic hypertension 342 52 22.3 that they saw a physician stated that the physician had
Total 233 100.0 confirmed the screening diagnose(s) (Table 4).
DISCUSSION
The KEEP Pilot screening program demonstrated thatTable 3. Number of participants learning of an abnormality that
placed them at increased risk targeted screenings are an effective means of identifying
persons at risk for kidney disease, and can identify indi-N with % of 514 subjects with
viduals at risk early enough in the course of their diseaseLearned of risk of finding % abnormal findings
to allow for effective intervention. The screening identi-Diabetesa 27 4.3 5.3
Hypertensionb 180 28.7 35.0 fied risk factors for diabetes, hypertension and/or kidney
Kidney diseasec 420 67.0 81.7 disease in 71.4% of individuals screened. The largest
Total 627 100.0
group of individuals screened was between 35 and 54
a Serum glucose 140 mg/dL years, an age group in which intervention might be ex-b Systolic blood pressure 140 mm Hg and/or diastolic blood pressure 90
mm Hg pected to have maximal benefit.
c Increased serum creatinine (women 1.2 mg/dL; men 1.4 mg/dL) and/or The program also was effective in motivating some,microalbuminuria, hematuria, pyuria
but not all, persons with abnormal results to seek follow-
up with a physician. It is also not clear why there was
such a large discrepancy between abnormal test values
and confirmation of screening diagnosis. The follow upnine 2.0 mg/dL), 171 had microalbuminuria, 137 had
data were self-reported by the participants. Some of thepyuria and 165 had hematuria.
participants were not sure what their doctor did orOne hundred sixty-eight participants reported pre-
whether their treatment regimen changed. Others couldexisting diabetes mellitus. More than 1/3 of these persons
not remember what their doctor said. This lack of con-
had one or more additional risk factors identified: 61 firmation of diagnoses by the patient’s physician is dis-
had microalbuminuria; 33 had pyuria; 32 hematuria; 35 turbing and also may represent a lack of understanding
increased serum creatinine; 88 systolic hypertension and of the importance of even early signs of kidney disease
54 diastolic hypertension. Thirteen of 511 persons with by some physicians. Some of the patients were told, for
a family history of diabetes mellitus, 20 of 648 with a example, that a little protein in the urine was nothing
family history of hypertension, and 7 of 225 with a family to worry about, or that a slightly elevated serum creati-
history of kidney disease learned of their diabetes risk. nine was not of concern. In this regard, education of
primary care and other physicians and health care pro-Of those with a family history of diabetes, 46.7% learned
viders regarding significance of abnormal test valuesof a least one renal risk factor. Fifty seven per cent of
and appropriate interventions is particularly important.the participants identified with blood glucose greater
These results also underscore the importance of provid-than 140 mg/dL were not aware that they might have
ing physician and health care provider guidance for thediabetes. Either a positive family history of kidney dis-
appropriate management of risks in patients with chronicease or hypertension significantly increased the risk for
kidney disease.
a positive finding for individual subjects both for risk
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